Large study checks safety of common lymphoma drug in japanese patients
NCT ID NCT06790420
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study looked at medical records from over 2,700 people in Japan with a type of lymphoma (CD20-positive B-cell non-Hodgkin's lymphoma) who were treated with Rituximab Pfizer or Rituxan. The goal was to compare how often serious infections and low blood cell counts happened. The study did not test a new treatment, but instead gathered information to better understand the safety of these drugs in real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.